Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-03-30 Annual Report
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Rapport financier annuel
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL EXERCICE 2017' (Annual Financial Report for the 2017 fiscal year) for the company Nanobiotix S.A. It contains a comprehensive summary, management report (Rapport de gestion), consolidated financial statements, and audit reports. This aligns perfectly with the definition of an Annual Report (10-K equivalent for non-US entities). FY 2017
2018-03-30 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of February 28, 2018. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Since it reports on the total number of shares and voting rights, it most closely aligns with notifications regarding capital structure changes or major shareholdings. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit as it deals directly with the composition of the capital, although 'Major Shareholding Notification' (MRQ) is also related to capital structure thresholds. However, this specific report is a mandatory monthly disclosure of the *total* capital structure, which falls under the scope of capital changes/structure reporting. It is not an earnings release, an AGM material, or a director's dealing. I will classify it as SHA as it directly reports on the capital structure components.
2018-03-07 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of January 31, 2018. This type of mandatory periodic disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement in France, often related to major shareholding notifications or general capital structure updates. Given the options, this specific disclosure about the total number of shares and voting rights aligns most closely with notifications concerning significant share ownership changes or capital structure, which often fall under Major Shareholding Notification (MRQ) or general Regulatory Filings (RNS). Since it is a specific, recurring regulatory disclosure about the capital structure (total shares/votes), it is best classified as a Major Shareholding Notification (MRQ), as these reports often trigger when thresholds are crossed, and this report establishes the baseline for those thresholds. However, since the definition for MRQ is strictly 'Notification of changes in significant share ownership levels (crossing thresholds)', and this document reports the absolute total, it is a standard monthly disclosure required regardless of crossing a threshold. Therefore, the most appropriate general category for a mandatory, non-standard report like this, which doesn't fit 10-K, ER, or IR, is the general Regulatory Filings (RNS). If a more specific category existed for 'Total Voting Rights', RNS would be the fallback. Given the options, RNS is the safest classification for a mandatory regulatory disclosure that isn't a primary financial report or a specific insider/dividend announcement.
2018-02-05 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 22, 2018, announcing 'first readout of intermediate data on the safety and feasibility' of the NBTXR3 trial in liver cancers, presented at the ASCO GI annual meeting. It details preliminary safety and efficacy results (secondary endpoint) and discusses the trial protocol and future steps. This format—a formal announcement of clinical trial results and data presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full quarterly/interim financial report (IR) or a comprehensive Annual Report (10-K), and it specifically releases key financial/clinical performance highlights, the most appropriate classification is Earnings Release (ER). It is not a simple announcement of a report publication (RPA) because it contains the substantive data itself, not just a notice that data is available.
2018-01-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 22, 2018, announcing 'premières données prometteuses' (first promising data) from a Phase I/II clinical trial for NBTXR3 in liver cancers, presented at the ASCO GI Annual Meeting. It details safety, feasibility, and preliminary efficacy results (response rates). This format—a formal announcement of clinical trial results, often including tables and references to abstracts/posters—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses specifically on presenting interim clinical trial results and is not a full, comprehensive periodic financial report (like 10-K or IR), nor is it solely a management discussion (MDA), the most appropriate classification is Earnings Release (ER), as clinical trial updates often accompany or substitute for traditional earnings announcements in biotech/pharma, or it could be classified as a Regulatory Filing (RNS) if it were purely a regulatory disclosure. Given the structure highlighting key results and the context of presenting at a major medical meeting, ER is a strong fit for communicating period-specific operational/clinical performance highlights. However, since the core content is a clinical trial update presented at a conference, and it is not explicitly labeled as an 'Earnings Release' but rather a presentation of data, it functions as a significant operational update. In the absence of a specific 'Clinical Trial Update' code, and given that it is a formal announcement of results, ER (Earnings Release, often used for period results) or RNS (Regulatory Filing/General Announcement) are candidates. Given the detailed nature of the results presentation, it leans towards communicating performance metrics, making ER plausible, but RNS is the safest fallback for non-standard operational announcements. Since it is a detailed announcement of clinical progress, which is a key performance indicator, I will classify it as ER, as these often contain the most material non-financial updates for biotech firms.
2018-01-22 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 97% confidence The document is a press release dated January 11, 2018, announcing a preclinical research collaboration between Nanobiotix and Providence Cancer Institute regarding the product NBTXR3. It details the scope of the research, quotes key personnel, provides background on the institutions and the product, and includes contact information and a standard disclaimer. This format—a formal announcement of a business development, partnership, or research milestone, typically issued via wire services—does not fit the specific definitions for financial reports (10-K, IR, ER, MRQ), governance documents (DEF 14A, CGR), or meeting materials (AGM-R, PSI). Since it is a general, non-standard regulatory announcement that doesn't fit the other specific categories, the most appropriate classification is the general regulatory filing fallback category.
2018-01-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.